SCHEMBL4076235

SCHEMBL4076235

Cc1cccc(-c2cc3ncnc(NCCc4c(C)[nH]c5c(C)cccc45)c3s2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 1/20 0.43
FLT1 P17948 8/20 0.42
EGFR P00533 7/20 0.42
SYK P43405 1/20 0.41
KDR P35968 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TYK2 P29597 1/20 0.39
CLK4 Q9HAZ1 3/20 0.39
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37
TUBA1A Q71U36 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3939158 0.94 FLT1 (0.48) FLT1EGFRKDRNPC1RAB9A
SCHEMBL3931001 0.90 IKBKB (0.42) MAP3K8FLT1EGFRKDRNPC1
SCHEMBL4068884 0.89 TYK2 (0.53) MAP3K8FLT1EGFRKDRNPC1
SCHEMBL4069817 0.87 CYP1A2 (0.46) FLT1EGFRKDRCLK4MEN1
SCHEMBL4007903 0.87 STK17B (0.42) MAP3K8FLT1EGFRKDRNPC1
SCHEMBL3929417 0.87 STK17B (0.51) MAP3K8FLT1EGFRKDRNPC1
SCHEMBL13960063 0.85 NPC1 (0.44) FLT1EGFRKDRNPC1RAB9A
SCHEMBL4008652 0.85 CDK1 (0.41) MAP3K8FLT1EGFRSYKKDR
SCHEMBL3930923 0.84 NPC1 (0.42) MAP3K8FLT1EGFRSYKKDR
SCHEMBL4067376 0.82 FLT1 (0.48) MAP3K8FLT1EGFRKDRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP claimed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor BAYER SCHERING PHARMA AG (DE) 2009-02-12 US disclosed
WO-2009007421-A1 INDOLYLALKYLTHIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-01-15 WO disclosed
EP-2014662-A1 Indolyl alkyl thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma Aktiengesellschaft (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042913-A1 Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor PTGER2, PTGER1, PTGDR2 MAP3K8 1818/4885FLT1 3775/4885EGFR 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.